Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATE.
We report a successful treatment of a patient with heavily metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor, which was unresponsive to high doses of octreotide analog using peptide receptor radionuclide therapy applying a radiolabeled somatostatin analog. After the peptide receptor radionuclide therapy, there was a decrease in vasoactive intestinal polypeptide levels, a significant reduction in somatostatin receptor expression and in molecular tumor volume on 68Ga DOTANOC PET/CT scan, and a complete long-term resolution of symptoms of the patient.